# A single cell transcriptional profile of benign prostatic hyperplasia

**Authors:** Rei Unno, Jon Akutagawa, Hanbing Song, Keliana Hui, Yih-An Chen, Julia H. Pham, Jean Lee, Heiko Yang, Franklin W. Huang, Thomas Chi

PMC · DOI: 10.1038/s41598-025-02417-w · 2026-03-14

## TL;DR

This study uses single-cell RNA sequencing to analyze prostate tissue from men with benign prostatic hyperplasia, identifying cell subgroups linked to inflammation and a potential precursor cell type.

## Contribution

The study identifies a rare luminal cell subgroup with a stem cell-like signature and its interactions with immune and stromal cells via MIF in BPH.

## Key findings

- A rare luminal subgroup with a high stem cell signature was identified in BPH tissue.
- Ligand-receptor interactions involving MIF were found between the luminal subgroup and fibroblasts/macrophages.
- The luminal subgroup is suggested to be a progenitor state contributing to BPH inflammation and proliferation.

## Abstract

Benign prostatic hyperplasia (BPH) is characterized by excessive cell proliferation and inflammation and affects most aging men. The development of new therapies for BPH requires a deeper understanding of the underlying pathophysiology and cellular components of BPH. Single-cell RNA-sequencing was performed on prostate tissue from 15 patients undergoing holmium laser enucleation of the prostate for treatment of BPH. Clustering and differential expression analysis on aligned single-cell RNA-seq data was performed to annotate all cell types. 16,234 cells were analyzed and specific stromal, epithelial, and immune subgroups were found to be strongly associated with inflammation. A rare luminal subgroup was identified and pseudotime analysis indicated this luminal subgroup might give rise to other luminal cells. Using a gene set derived from epithelial stem cells, we found that this luminal subgroup had a significantly higher stem cell signature score than all other epithelial subgroups, suggesting this subgroup is a luminal precursor state. Ligand-receptor interactions between stromal, epithelial, and immune cells were explored with CellPhoneDB. Significant interactions involving MIF, a pro-inflammatory cytokine that promotes epithelial cell growth and inflammatory response in the prostate, were identified between the progenitor-like luminal subgroup and both fibroblasts and macrophages. Our single-cell profiling of BPH provides a roadmap for investigating inflammation-linked cell subgroups and highlights a progenitor-like luminal subgroup interacting with other cell groups via MIF that may contribute to the inflammation and cell proliferation phenotype associated with BPH.

The online version contains supplementary material available at 10.1038/s41598-025-02417-w.

## Linked entities

- **Genes:** MIF (macrophage migration inhibitory factor) [NCBI Gene 4282]
- **Diseases:** Benign prostatic hyperplasia (MONDO:0010811)

## Full-text entities

- **Genes:** CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, RPLP0 (ribosomal protein lateral stalk subunit P0) [NCBI Gene 6175] {aka L10E, LP0, P0, PRLP0, RPP0, uL10}, RPL12 (ribosomal protein L12) [NCBI Gene 6136] {aka L12, uL11}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, PALD1 (phosphatase domain containing paladin 1) [NCBI Gene 27143] {aka KIAA1274, PALD}, Mmp7 (matrix metallopeptidase 7) [NCBI Gene 17393] {aka MAT, MMP-7}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, FCGR3B (Fc gamma receptor IIIb) [NCBI Gene 2215] {aka CD16, CD16-I, CD16b, FCG3, FCGR3, FCRIIIb}, FCER1A (Fc epsilon receptor Ia) [NCBI Gene 2205] {aka FCE1A, FCERIA, FcERI}, Trp63 (transformation related protein 63) [NCBI Gene 22061] {aka Ket, P51/P63, P63, P73l, Tp63, Trp53rp1}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, TNFRSF10D (TNF receptor superfamily member 10d) [NCBI Gene 8793] {aka CD264, DCR2, TRAIL-R4, TRAILR4, TRUNDD}, KLK4 (kallikrein related peptidase 4) [NCBI Gene 9622] {aka AI2A1, ARM1, EMSP, EMSP1, KLK-L1, PRSS17}, RPL27A (ribosomal protein L27a) [NCBI Gene 6157] {aka L27A, uL15}, CD1C (CD1c molecule) [NCBI Gene 911] {aka BDCA1, CD1, R7}, GJC1 (gap junction protein gamma 1) [NCBI Gene 10052] {aka CX45, GJA7}, CXCR2 (C-X-C motif chemokine receptor 2) [NCBI Gene 3579] {aka CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB}, CX3CR1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 1524] {aka CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28}, FOLR2 (folate receptor beta) [NCBI Gene 2350] {aka BETA-HFR, FBP, FBP/PL-1, FR-BETA, FR-P3, FRbeta}, MIF (macrophage migration inhibitory factor) [NCBI Gene 4282] {aka GIF, GLIF, MMIF}, KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}, MT2A (metallothionein 2A) [NCBI Gene 4502] {aka MT-2, MT-II, MT2}, VCAN (versican) [NCBI Gene 1462] {aka CSPG2, ERVR, GHAP, PG-M, WGN, WGN1}, DNASE1L3 (deoxyribonuclease 1L3) [NCBI Gene 1776] {aka D3, DHP2, DNAS1L3, LSD, SLEB16}, C7 (complement C7) [NCBI Gene 730], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, RGS5 (regulator of G protein signaling 5) [NCBI Gene 8490] {aka MST092, MST106, MST129, MSTP032, MSTP092, MSTP106}, FBLN1 (fibulin 1) [NCBI Gene 2192] {aka FBLN, FIBL1}, NKX3-1 (NK3 homeobox 1) [NCBI Gene 4824] {aka BAPX2, NKX3, NKX3.1, NKX3A}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59] {aka ACTSA, SMDYS}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, KLK2 (kallikrein related peptidase 2) [NCBI Gene 3817] {aka KLK2A2, hGK-1, hK2}, Pigr (polymeric immunoglobulin receptor) [NCBI Gene 18703], TNFRSF14 (TNF receptor superfamily member 14) [NCBI Gene 8764] {aka ATAR, CD270, HVEA, HVEM, LIGHTR, TR2}, PLXDC1 (plexin domain containing 1) [NCBI Gene 57125] {aka TEM3, TEM7}, BMP5 (bone morphogenetic protein 5) [NCBI Gene 653], RPL13A (ribosomal protein L13a) [NCBI Gene 23521] {aka L13A, TSTA1, uL13}, C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, HOXB13 (homeobox B13) [NCBI Gene 10481] {aka HPC9, PSGD}, Scgb3a1 (secretoglobin, family 3A, member 1) [NCBI Gene 68662] {aka HIN-1, LuLeu2, Pnsp2, UGRP2, Utgrp2}, LUM (lumican) [NCBI Gene 4060] {aka LDC, SLRR2D}, RPL7A (ribosomal protein L7a) [NCBI Gene 6130] {aka L7A, SURF3, TRUP, eL8}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, ACP3 (acid phosphatase 3) [NCBI Gene 55] {aka 5'-NT, ACP-3, ACPP, TM-PAP}, Krt5 (keratin 5) [NCBI Gene 110308] {aka 3300001P10Rik, CK5, K5, Krt2-5, Tfip8}, DCN (decorin) [NCBI Gene 1634] {aka CSCD, DSPG2, PG40, PGII, PGS2, SLRR1B}, JCHAIN (joining chain of multimeric IgA and IgM) [NCBI Gene 3512] {aka IGCJ, IGJ, JCH}, MYH11 (myosin heavy chain 11) [NCBI Gene 4629] {aka AAT4, FAA4, SMHC, SMMHC, SMMS-1, VSCM2}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, IER3 (immediate early response 3) [NCBI Gene 8870] {aka DIF-2, DIF2, GLY96, IEX-1, IEX-1L, IEX1}, CD14 (CD14 molecule) [NCBI Gene 929], TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CD207 (CD207 molecule) [NCBI Gene 50489] {aka CLEC4K}
- **Diseases:** BPH (MESH:D011470), LUTS (MESH:D059411), prostate, breast, and ovarian cancers (MESH:D010051), psoriasis (MESH:D011565), atherosclerosis (MESH:D050197), prostate tumor (MESH:D011472), inflammation (MESH:D007249), autoimmune disease (MESH:D001327), prostate cancer (MESH:D011471), atrophy (MESH:D001284), UMAP (MESH:C567162), cancer (MESH:D009369), fibrosis (MESH:D005355)
- **Chemicals:** HCl (MESH:D006851), oligonucleotides (MESH:D009841), SDS (MESH:D012967), MgCl2 (MESH:D015636), eosin (MESH:D004801), Hematoxylin (MESH:D006416), CPSI-1306 (MESH:C000598334), dihydrotestosterone (MESH:D013196), EDTA (MESH:D004492), water (MESH:D014867), NaOH (MESH:D012972), HEPES (MESH:D006531), benzoxazole-2-thione (MESH:C525534), PEG8000 (MESH:C000595216), NaCl (MESH:D012965), N-acetyl-p-benzoquinone imine (MESH:C028473), citrate (MESH:D019343), TE (MESH:D013691), Maxima RT buffer (-), luminal (MESH:D010634), H&amp;E (MESH:D006371), guanidine thiocyanate (MESH:C054436), sarkosyl (MESH:C025231), holmium (MESH:D006695)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** N0447L, M0212L
- **Cell lines:** peFib — Homo sapiens (Human), Finite cell line (CVCL_1E62)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13009279/full.md

---
Source: https://tomesphere.com/paper/PMC13009279